Antares Pharma (NASDAQ:ATRS) CEO Paul Wotton unloaded 35,000 shares of Antares Pharma stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $4.42, for a total transaction of $154,700.00. Following the completion of the sale, the chief executive officer now directly owns 708,734 shares of the company’s stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Oppenheimer initiated coverage on shares of Antares Pharma in a research note to investors on Friday, June 21st. They set an “outperform” rating and a $6.00 price target on the stock.
Antares Pharma (NASDAQ:ATRS) opened at 4.39 on Tuesday. Antares Pharma has a 1-year low of $3.35 and a 1-year high of $4.86. The stock’s 50-day moving average is currently $4.32. The company’s market cap is $553.9 million.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $4.50 million for the quarter, compared to the consensus estimate of $5.12 million. The company’s revenue for the quarter was down 34.5% on a year-over-year basis. Analysts expect that Antares Pharma will post $-0.12 EPS for the current fiscal year.
Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.